Rapid symptom relief is a key treatment goal in active ulcerative colitis.
References: 1. Sninsky CA et al. Gastroenterology & Hepatology. 2008;4(suppl 4):1-10.
According to the ACG* Guidelines, improving symptoms during an active ulcerative colitis flare is a key goal of therapy.1
* American College of Gastroenterology.
References: 1. Kornbluth A et al. Am J Gastroenterol. 2004;99:1371-1385. 2. Sninsky CA et al. Gastroenterology & Hepatology. 2008;4(suppl 4):1-10.
Efficacy throughout the colon is important when choosing an ulcerative colitis therapy.
References: 1. Data on file, Procter & Gamble Pharmaceuticals, Inc. 2. Sninsky CA et al. Gastroenterology & Hepatology. 2008;4(suppl 4):1-10.
Efficacy throughout the colon is important when choosing an UC therapy.
References: 1. Data on file, Procter & Gamble Pharmaceuticals, Inc. 2. Sninsky CA et al. Gastroenterology & Hepatology. 2008;4(suppl 4):1-10.
Selected Safety Information
Asacol is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses).In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo, respectively, were headache (35% vs 36%), abdominal pain (18% vs 14%), and eructation (16% vs 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs 50%), rhinitis (42% vs 36%) , and diarrhea (35% vs 50%).
Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol.
Please see accompanying full prescribing information by clicking the link above.
